Journal article
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Abstract
BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.
METHODS: We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants with stable cardiovascular disease and …
Authors
Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH
Journal
Gastroenterology, Vol. 157, No. 3, pp. 682–691.e2
Publisher
Elsevier
Publication Date
9 2019
DOI
10.1053/j.gastro.2019.05.056
ISSN
0016-5085
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAspirinCardiovascular DiseasesDouble-Blind MethodDrug Administration ScheduleEnterocolitis, PseudomembranousFactor Xa InhibitorsFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPantoprazolePeripheral Arterial DiseasePlatelet Aggregation InhibitorsProspective StudiesProton Pump InhibitorsRisk AssessmentRisk FactorsRivaroxabanTime FactorsTreatment Outcome